scholarly journals PINCH Protein Expression in Normal Endometrium, Atypical Endometrial Hyperplasia and Endometrioid Endometrial Carcinoma

Chemotherapy ◽  
2010 ◽  
Vol 56 (4) ◽  
pp. 291-297 ◽  
Author(s):  
Hong-Zhen Zhang ◽  
Xue-Hui Li ◽  
Xia Zhang ◽  
Zhi-Yong Zhang ◽  
Ya-Li Meng ◽  
...  
Keyword(s):  
Protein Expression ◽  
Endometrial Carcinoma ◽  
Endometrial Hyperplasia ◽  
Normal Endometrium ◽  
Atypical Endometrial Hyperplasia ◽  
Endometrioid Endometrial Carcinoma

scholarly journals Cyclical change of hMSH2 protein expression in normal endometrium during the menstrual cycle and its overexpression in endometrial hyperplasia and sporadic endometrial carcinoma

Cancer ◽  
2002 ◽  
Vol 94 (4) ◽  
pp. 997-1005 ◽  
Author(s):  
Atia A. Hamid ◽  
Masaki Mandai ◽  
Ikuo Konishi ◽  
Kanako Nanbu ◽  
Yuko Tsuruta ◽  
...  
Keyword(s):  
Menstrual Cycle ◽  
Protein Expression ◽  
Endometrial Carcinoma ◽  
Endometrial Hyperplasia ◽  
Normal Endometrium ◽  
Cyclical Change

scholarly journals Loss of ten-eleven translocation 1 (TET1) expression as a diagnostic and prognostic biomarker of endometrial carcinoma

PLoS ONE ◽  
2021 ◽  
Vol 16 (11) ◽  
pp. e0259330
Author(s):  
Nien-Tzu Liu ◽  
Cherng-Lih Perng ◽  
Yu-Ching Chou ◽  
Pi-Shao Ko ◽  
Yi-Jia Lin ◽  
...  
Keyword(s):  
Differential Diagnosis ◽  
Endometrial Carcinoma ◽  
Endometrial Hyperplasia ◽  
Expression Profiles ◽  
Gynecological Cancer ◽  
Dna Demethylation ◽  
Atypical Hyperplasia ◽  
Mrna Levels ◽  
Normal Endometrium ◽  
Expression Score

Endometrial carcinoma (EC) is the most common gynecological cancer. However, there is currently no routinely used biomarker for differential diagnosis of malignant and premalignant endometrial lesions. Ten-eleven translocation (TET) proteins, especially TET1, were found to play a significant role in DNA demethylation, via conversion of 5-methylcytosine (5-mC) to 5-hydroxymethylcytosine (5-hmC). TET1, 5-mC, and 5-hmC expression profiles in endometrial carcinogenesis are currently unclear. We conducted a hospital-based retrospective review of the immunohistochemical expression of TET1, 5-mC, and 5-hmC in 181 endometrial samples. A “high” TET1 and 5-hmC expression score was observed in all cases of normal endometrium (100.0% and 100.0%, respectively) and in most samples of endometrial hyperplasia without atypia (90.9% and 78.8%, respectively) and atypical hyperplasia (90.6% and 93.8%, respectively), but a “high” score was found in only less than half of the EC samples (48.8% and 46.5%, respectively). The TET1 and 5-hmC expression scores were significantly higher in normal endometrium and premalignant endometrial lesions than in ECs (p < 0.001). A “high” 5-mC expression score was observed more frequently for ECs (81.4%) than for normal endometrium (40.0%), endometrial hyperplasia without atypia (51.5%), and atypical hyperplasia (53.1%) (p < 0.001). We also found that TET1 mRNA expression was lower in ECs compared to normal tissues (p = 0.0037). TET1 immunohistochemistry (IHC) scores were highly proportional to the TET1 mRNA levels and we summarize that the TET1 IHC scoring can be used for biomarker determinations. Most importantly, a higher TET1 score in EC cases was associated with a good overall survival (OS) rate, with a hazard ratio (HR) of 0.31 for death (95% confidence interval: 0.11–0.84). Our findings suggest that TET1, 5-mC, and 5-hmC expression is a potential histopathology biomarker for the differential diagnosis of malignant and premalignant endometrial lesions. TET1 is also a potential prognostic marker for EC.

Which surgical procedure for patients with atypical endometrial hyperplasia?

2005 ◽  
Vol 15 (1) ◽  
pp. 127-131 ◽  
Author(s):  
B. S. Karamursel ◽  
S. Guven ◽  
G. Tulunay ◽  
T. Kucukali ◽  
A. Ayhan
Keyword(s):  
Endometrial Carcinoma ◽  
Endometrial Hyperplasia ◽  
Menopausal Status ◽  
Endometrial Biopsy ◽  
Surgical Staging ◽  
Lymph Node Status ◽  
Atypical Endometrial Hyperplasia ◽  
Group I ◽  
Significant Difference ◽  
Group Ii

ObjectiveTo determine the occult coexistence of endometrial carcinoma in patients with atypical endometrial hyperplasia and to compare histological prognostic factors according to lymph node status in occult endometrial carcinoma.Materials and MethodsTwo hundred and four patients from two referral centers (during the period 1990–2003) who were operated on within 1 month of endometrial biopsy for symptomatic endometrial hyperplasia without receiving any medical treatment were included retrospectively. Patients having preoperative endometrial biopsy results of concomitant endometrial hyperplasia and carcinoma were excluded from the study. Fifty-six patients having atypia in preoperative biopsy (group I) were compared with 148 patients without atypia (group II). Chi-square and Mann–Whitney U-tests were used for statistical analyses.ResultsNo significant difference was observed between the two groups according to age or menopausal status. Patients in group II had significantly higher parity than patients in group I. In group I, 62.5% of the patients had endometrial carcinoma, 21.4% had endometrial hyperplasia, and 16.1% had normal endometrium in hysterectomy specimens. In group II, the percentages were 5.4, 38.5, and 56.1%, respectively. Complete surgical staging was performed in 20 patients. Four patients had metastatic lymph nodes. All of them had grade 2 tumors with lymphovascular space involvement. Three of them had nonendometrioid tumors.ConclusionCareful intraoperative and preoperative evaluation of the endometrium must be the sine qua non for patients with atypical endometrial hyperplasia. It is reasonable to do frozen section at the time of hysterectomy for atypical endometrial hyperplasia, and if grade 2/3 of nonendometriod cancer with lymphovascular space involvement is found, complete surgical staging should be performed.

Young Nulliparous Female with Continous Vaginal Bleeding: A Case of Atypical Endometrial Hyperplasia

2018 ◽  
Vol 3 (6) ◽  
Keyword(s):  
Endometrial Carcinoma ◽  
Vaginal Bleeding ◽  
Endometrial Hyperplasia ◽  
Definitive Treatment ◽  
Atypical Endometrial Hyperplasia ◽  
Dilatation And Curettage ◽  
One Year ◽  
Nulliparous Female ◽  
Secretory Endometrium ◽  
Continuous Bleeding

Mrs. XYZ 32 years of age, nulliparous presented in the OPD with complaint of continuous vaginal bleeding for 1 month. She had had Dx D & C twice previously for the same complaint one year ago. The two H/P reports showed Adenocarcinoma of the Uterus and repeat D & C one month later showed Secretory endometrium. Dilatation and curettage was done again on19. 03 2018 which showed Atypical Endometrial Hyperplasia (AEH). The couple was counseled and they opted for definitive treatment. TAH & BSO was done on 03.04 2018. Cut section showed thickened endometrium with no myometrium invasion. Conclusion: In patients with irregular or continuous bleeding P/V should be evaluated for AEH or Endometrial carcinoma.

Sign in / Sign up

Export Citation Format

Share Document